Creating a new treatment to remove amyloid deposits in patients with systemic amyloidosis
Official title: Development of a Theranostic Immunotherapy for Systemic Amyloidosis
Funded at University of Tennessee Health Sci Ctr · NIH-10792590 · Data updated 2026-11-12
This study is testing a new treatment that uses special antibodies to help your immune system remove harmful amyloid deposits from your body if you have systemic amyloidosis, with the hope of improving your health and making future treatments more effective.
Quick facts
| Grant type | R01 grant |
|---|---|
| Study type | NIH-funded research |
| Funding institution | University of Tennessee Health Sci Ctr NIH-funded |
| Lab location | 1 site (Memphis, United States) |
| Project start | March 1, 2021 |
| Project end | February 28, 2026 |
| Funding year | 2024 |
| Award (this year) | $425,568 |
| NIH project number | 5R01DK123001-04 |
| Project ID | NIH-10792590 on NIH RePORTER |
Who could benefit from this research
✓Could help
Ideal candidates for this research are patients diagnosed with systemic amyloidosis who have significant amyloid deposits affecting their organs.
✕Less likely to help
Patients who do not have systemic amyloidosis or those with early-stage disease without significant amyloid burden may not benefit from this research.
What this research studies
This research focuses on developing a novel immunotherapy that targets and removes amyloid deposits from tissues in patients suffering from systemic amyloidosis. The approach involves using specially designed antibodies, known as peptibodies, which can bind to amyloid and recruit immune cells to clear it from the body. By utilizing molecular imaging techniques, the researchers aim to enhance the selection of patients for clinical trials and improve treatment outcomes. The ultimate goal is to create a therapy that not only reduces the production of amyloid-forming proteins but also effectively eliminates existing amyloid deposits.
Why it matters
Potential benefit: If successful, this research could significantly improve the survival and quality of life for patients with systemic amyloidosis by effectively clearing harmful amyloid deposits from their tissues.
How similar studies have gone: Previous research has shown success with similar immunotherapy approaches in targeting amyloid deposits, indicating a promising avenue for treatment.
Where this research is happening
-
University of Tennessee Health Sci Ctr
Memphis, United States Active
Researchers
- Principal investigator: Wall, Jonathan S — University of Tennessee Health Sci Ctr
- Study coordinator: Wall, Jonathan S
Related research
Other NIH-funded projects on the same topics.
-
Boosting immune response to fight cancer
This study is exploring a new way to help your immune system better fight cancer by tweaking certain cells in your body, and it aims to improve treatment for people with advanced cancer.
-
A center focused on immunotherapy for pediatric cancers.
This study is exploring new ways to use the body's immune system to fight childhood cancers, aiming to create better treatments for kids whose cancers haven't responded well to standard therapies.
-
Algorithms to find HLA-E neoantigens for cancer immunotherapy
Aims to develop computer methods to discover tumor-specific targets presented by HLA-E to guide new T cell therapies for cancer.
-
Immunotherapy for glioblastoma: advancing treatment and understanding
A patient-friendly summary of a grant exploring new immune-based treatments for glioblastoma to improve options for people affected by this brain cancer.
-
How CRISPR-based gene activation could shape immunotherapy responses in clear cell cancers
A research project at Stanford is using CRISPR-based gene activation to understand why some clear cell ovarian and kidney cancers respond to immunotherapy while others do not.
-
Hybrid biomaterial system to boost immunotherapy for rheumatoid arthritis
A new, patient-facing immunotherapy approach uses specialized particles to retrain the immune system to calm RA in adults.
About this research
- This is an active NIH-funded research project — typically early-stage science, not a clinical trial accepting patient enrollment.
- Some NIH-funded labs run parallel clinical studies or seek volunteers for related work. To check, contact the principal investigator or institution listed above.
- For full project details, budget, and progress reports, visit the official NIH RePORTER page.